for the future
Achieving higher standards for what today's patients
Controlling for the future of TAVI patients
Patients with longer life expectancies require additional considerations for TAVI procedures
Click each tab for more related information
PARTNER 3 Trial low-risk bicuspid nested registry1,2,7
All-cause death, all stroke, or rehospitalization through 1 year1
The need for post-TAVI coronary access is expected to increase in patients with
longer life expectancies
Excellent outcomes in appropriate bicuspid patients
TVT registry data4View next topic
Excellent SAPIEN 3 valve durability at 5 years in PARTNER II Trial5
Low rates of SVD and SVD-related BVF
*Stage 2 & 3 (moderate & severe HVD): morphological valve deterioration AND +Δ mean gradient ≥ 10 mmHg with final mean gradient ≥ 20 mmHG§ and any of: -Δ AVA ≥ 0.3 cm2 (or ≥ 25%)§, -Δ DVI ≥ 0.1 (or ≥ 20%)§ OR ≥ 1 grade Δ transvalvular AR with final grade ≥ moderate.
†Stage 3 (severe HVD): morphological valve deterioration AND +Δ mean gradient ≥ 20 mmHG with final mean gradient ≥ 30 mmHg§ and any of: -Δ AVA ≥ 0.6 cm2 (or ≥ 50%)§, -Δ ≥ 0.2 (or ≥ 40%)§ OR ≥ 2 grade Δ transvalvular AR with severe final grade.
‡In this study, we used PARTNER II propensity matched data to analyze SVD rates, there was no statistically significant difference between SAPIEN 3 TAVI and SAVR for all endpoints except for all-cause BVF. The majority of cases within all-cause BVF in SAVR were due to endocarditis, while in TAVI they were due to paravalvular AR, a form of nonstructural valve dysfunction.
§Compared to echocardiographic assessment performed 1 to 3 months post-procedure (or discharge if not available).View next topic
The only valve approved for aortic THV-in-THV and transseptal mitral
Treatment options with SAPIEN 3 TAVI
Designed for future coronary access, validated by data
Resource CenterView All Resources